Othera Pharmaceuticals, a specialty pharmaceutical company, has initiated dosing in a Phase I/II clinical trial to determine the safety and efficacy of topical OT-730 in patients with ocular hypertension and glaucoma.

Othera Pharmaceuticals has submitted an investigational new drug application to the FDA for OT-730, an oculoselective beta-blocker, as a potential treatment for glaucoma. A Phase I-II safety and efficacy trial is planned for completion by the end of 2008.